Long-term results of total therapy studies 11, 12 and 13A for childhood acute lymphoblastic leukemia at St Jude children's research hospital

Leukemia

Volumn 14, Issue 12, 2000, Pages 2286-2294

  Pui, C H ^a,b   Boyett, J M ^a   Rivera, G K ^a,b   Hancock, M L ^a   Sandlund, J T ^a,b   Ribeiro, R C ^a,b   Rubnitz, J E ^a,b   Behm, F G ^a   Raimondi, S C ^a   Gajjar, A ^a,b   Razzouk, B ^a,b   Campana, D ^a,b   Kun, L E ^a   Relling, M V ^a,c   Evans, W E ^a,c  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

B lineage ALL; Chemotherapy; CNS relapse; Leukemia; Prognostic factors; T lineage ALL

Indexed keywords

ANTILEUKEMIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; ASPARAGINASE; CD19 ANTIGEN; CD22 ANTIGEN; CD5 ANTIGEN; CD7 ANTIGEN; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DNA; DRUG METABOLITE; ETOPOSIDE; GLUCOCORTICOID; HYDROCORTISONE; MERCAPTOPURINE; METHOTREXATE; METHOTREXATE POLYGLUTAMATE; MONOCLONAL ANTIBODY; PREDNISONE; TENIPOSIDE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AGE; ARTICLE; B CELL LEUKEMIA; CANCER DIAGNOSIS; CANCER RECURRENCE; CANCER RISK; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM DISEASE; CHILD; CHILDHOOD LEUKEMIA; CLINICAL STUDY; CONTROLLED STUDY; DATA ANALYSIS; DRUG EFFICACY; FEMALE; GENETIC DISORDER; HUMAN; INFANT; INFORMATION PROCESSING; LEUKOCYTE COUNT; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MEDICAL RESEARCH; MINIMAL RESIDUAL DISEASE; PEDIATRIC HOSPITAL; PRIORITY JOURNAL; PROGNOSIS; RECURRENCE RISK; RISK ASSESSMENT; SEX DIFFERENCE; SURVIVAL RATE; T CELL LEUKEMIA; TREATMENT OUTCOME; UNITED STATES;

EID: 17744383161     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2401938     Document Type: Article

References (41)

1. L-asparaginase may potentiate the leukemogenic effect of the epipodophyllotoxins
2. Treatment of acute lymphoblastic leukemia. 30 years' experience at St Jude children's research hospital
3. Improved outcome in childhood acute lymphoblastic leukaemia with reinforced early treatment and rotational combination chemotherapy
4. Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia
5. Early intensification of intrathecal chemotherapy virtually eliminates central nervous system relapse in children with acute lymphoblastic leukemia
6. Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lymphoblastic leukemia
7. Blast cell methotrexatepolyglutamate accumulation in vivo differs by lineage, ploidy, and methotrexate dose in acute lymphoblastic leukemia
8. Differences in constitutive and post-methotrexate folylpolyglutamate synthetase activity in B-lineage and T-lineage leukemia
9. Differences in folypolyglutamate synthetase and dihydrofolate reductase expression in human B-lineage versus T-lineage leukemic lymphoblasts: Mechanisms for lineage differences in methotrexate polyglutamylation and cytotoxicity
10. Clinical and biologic relevance of immunologic marker studies in childhood acute lymphoblastic leukemia
11. Philadelphia chromosome-positive acute lymphoblastic leukemia in children: Durable responses to chemotherapy associated with low initial white blood cell counts
12. Evaluation of survival data and two new rank order statistics arising in its consideration
13. A class of K-sample tests for comparing the cumulative incidence of a competing risk
14. Late effects in survivors of infant leukemia
15. Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia
16. Results of the Dana-Farber Cancer Institute (DFCI) consortium protocol 91-01 for children with acute lymphoblastic leukemia (ALL)
17. Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy
18. Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: Results of trial ALL-BFM 90
19. Intensified therapy for infants with acute lymphoblastic leukemia: Results from the Dana-Farber Cancer Institute Consortium
20. Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia
21. Activity of an ABL specific tyrosine kinase inhibitor in patients with BCR-ABL positive acute leukemias, including chronic myelogenous leukemia in blast crisis
22. Die Corticosteroid-abhängige Dezimierung der Luekämiezellzahl im Blut als Prognosefaktor bei der akuten lymphoblastischen Leukämie im kindesalter (Therpiestudie ALL-BFM 83) (The in vivo response on an additional prognostic factor in childhood acute lymphoblastic leukemia (therapy study ALL-BFM 83))
23. Early response to therapy and outcome in childhood acute lymphoblastic leukemia
24. Clearance of marrow infiltration after 1 week of therapy for childhood lymphoblastic leukemia: Clinical importance and the effect of daunorubicin
25. Persistence of circulating blasts after 1 week of multiagent chemotherapy confers a poor prognosis in childhood acute lymphoblastic leukemia
26. Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia
27. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia
28. Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood
29. New definition of remission in childhood acute lymphoblastic leukemia
30. Sequential monitoring of minimal residual disease in childhood acute lymphoblastic leukemia
31. Drug therapy. Acute lymphoblastic leukemia
32. Low leukocyte counts with blast cells in cerebrospinal fluid of children with newly diagnosed acute lymphoblastic leukemia
33. Traumatic lumbar puncture at diagnosis adversely affects outcome in childhood acute lymphoblastic leukemia
34. Prognostic importance of 6-mercaptopurine dose intensity in acute lymphoblastic leukemia
35. Topoisomerase II inhibitor-related acute myeloid leukemia
36. Etoposide and antimetabolite pharmacology in patients who develop secondary acute myeloid leukemia
37. High incidence of secondary brain tumours after radiotherapy and antimetabolites
38. Pharmacogenomics: Translating functional genomics into rational therapeutics
39. L-asparaginase may potentiate the leukemogenic effect of the epipodophyllotoxins